Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,181–1,190 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1181
- Medicine slug
- pazopanib
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:115eb5bb-1403-fb3d-e063-6394a90ad320 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Administration of a single 400-mg crushed tablet increased AUC 0-72h by 46% and C max by approximately 2-fold and decreased T max by approximately 2 hours compared with administration of the whole tablet [see Dosage and Administration ( 2.1 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f7ea520-a152-401e-b1f7-b5ef8c7a2239 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Administration of a single 400-mg crushed tablet increased AUC 0-72h by 46% and C max by approximately 2-fold and decreased T max by approximately 2 hours compared with administration of the whole tablet [see Dosage and Administration ( 2.1 )] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16c5df52-0031-034d-e063-6294a90a1717 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Administration of a single 400-mg crushed tablet increased AUC 0-72h by 46% and C max by approximately 2-fold and decreased T max by approximately 2 hours compared with administration of the whole tablet [see Dosage and Administration ( 2.1 )] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b05ea49a-a764-5ff2-6e4a-26add69da9e2 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Administration of a single 400-mg crushed tablet increased AUC 0-72h by 46% and C max by approximately 2-fold and decreased T max by approximately 2 hours compared with administration of the whole tablet [see Dosage and Administration ( 2.1 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3e8dd09-d7d2-43da-8f63-bdf0ea0fcdf5 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Administration of a single 400-mg crushed tablet increased AUC 0-72h by 46% and C max by approximately 2-fold and decreased T max by approximately 2 hours compared with administration of the whole tablet [see Dosage and Administration (2.1)] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25575cc6-5757-4f9b-9c09-0c4deb61ba12 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Administration of a single 400 mg crushed tablet increased AUC 0-72h by 46% and C max by approximately 2-fold and decreased T max by approximately 2 hours compared with administration of the whole tablet [see Dosage and Administration (2.1) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Administration of a single 400-mg crushed tablet increased AUC 0-72h by 46% and C max by approximately 2-fold and decreased T max by approximately 2 hours compared with administration of the whole tablet [see Dosage and Administration (2.1)] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7235fad0-eb5b-4fdf-a362-c8c65c9bfe1d (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Administration of a single 400-mg crushed tablet increased AUC 0 to 72h by 46% and C max by approximately 2-fold and decreased T max by approximately 2 hours compared with administration of the whole tablet [see Dosage and Administration ( 2.1 )] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25305d33-caa0-4577-8b7b-06e430c34c39 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Administration of a single 400-mg crushed tablet increased AUC 0-72h by 46% and C max by approximately 2-fold and decreased T max by approximately 2 hours compared with administration of the whole tablet [see Dosage and Administration (2.1) ] .
Projected row 1182
- Medicine slug
- pegcetacoplan
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
4.5 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4434e61-9ec9-4e0e-bd60-45aaa0a87e64 (opens source in a new tab)
Pegcetacoplan label
Version not recorded · Effective date not recorded
Elimination The estimated geometric mean (%CV) of clearance (CL) is 0.284 L/day (21.1%) and geometric mean half-life of elimination (t 1/2 ) is 4.5 days (21.1%) in patients with GA.
8.6 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c23d89e9-b00b-4520-e053-2995a90a95af (opens source in a new tab)
Pegcetacoplan label
Version not recorded · Effective date not recorded
Elimination The estimated mean (CV%) of clearance (CL) is 0.36 L/day (30%) and median effective half-life of elimination (t 1/2 ) is 8.6 days in patients with PNH.
Projected row 1183
- Medicine slug
- pegcetacoplan
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
1.85 L
- Numeric value
- 1.85
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4434e61-9ec9-4e0e-bd60-45aaa0a87e64 (opens source in a new tab)
Pegcetacoplan label
Version not recorded · Effective date not recorded
Distribution The geometric mean (95%CI) volume of distribution of pegcetacoplan is approximately 1.85 L (1.62 - 2.12) in patients with GA following intravitreal administration.
3.98 L
- Numeric value
- 3.98
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c23d89e9-b00b-4520-e053-2995a90a95af (opens source in a new tab)
Pegcetacoplan label
Version not recorded · Effective date not recorded
Distribution The mean (CV%) volume of distribution of pegcetacoplan is approximately 3.98 L (32%) in patients with PNH.
Projected row 1184
- Medicine slug
- pegfilgrastim
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
15 to 80 hours
- Numeric value
- 15
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdfe5d72-6b80-435a-afa4-c5d74dd852ce (opens source in a new tab)
Pegfilgrastim label
Version not recorded · Effective date not recorded
The half-life of Neulasta ranged from 15 to 80 hours after subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeadd641-573d-47fe-897a-61006e5f9e03 (opens source in a new tab)
Pegfilgrastim label
Version not recorded · Effective date not recorded
The half-life of pegfilgrastim ranged from 15 to 80 hours after subcutaneous injection.
Projected row 1185
- Medicine slug
- pegfilgrastim-cbqv
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
15 to 80 hours
- Numeric value
- 15
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77a8576f-b91e-42ce-b613-2fa3c3d4a571 (opens source in a new tab)
Pegfilgrastim-Cbqv label
Version not recorded · Effective date not recorded
The half-life of pegfilgrastim ranged from 15 to 80 hours after subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8c290ee-b699-4395-a596-1453d4a4b4eb (opens source in a new tab)
Pegfilgrastim-Cbqv label
Version not recorded · Effective date not recorded
The half-life of pegfilgrastim ranged from 15 to 80 hours after subcutaneous injection.
Projected row 1186
- Medicine slug
- pemetrexed
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 32
- Source count
- 32
- Agreement rate
- 1
- Recorded readings
3.5 hours
- Numeric value
- 3.5
- Unit
- hours
- Source records
- 32
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 32 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f006b06-ab85-423d-ba0c-dfc3fc25844e (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfd19e67-54cb-c062-e053-2995a90a294a (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39219e4b-80a6-4d4f-96a3-1202e542d050 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0d000a3-b9d2-4fa9-9591-f7acb077481d (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fb3a2d5-b9ec-4044-abb9-3e0d848a448e (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2308f4e8-21c8-49c1-a5b8-deb8610bac6a (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64f4a9ed-26ff-4bc7-bef1-4faa98b35563 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cc1574b-3d2f-489b-9ad3-55695bb97200 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa8f1f52-3f05-4ae8-bfec-7f0a029e6825 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adc9ce4c-926a-4ee8-bd0d-d06fc89c17fc (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e087418-69ff-47fa-93c2-f28699309433 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae77f00f-d43b-4b75-afd5-a2a9cb7138da (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b660f68-b770-4e0a-b2f9-25e663deecc3 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ae68628-7ab0-4491-b3ae-6a8330b719c8 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:caef07ce-066b-4c48-98dc-974b05ebbbe0 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5a860f3-37ec-429c-ae04-9c88d7c55c08 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ca1ce75-5284-4282-b76a-3700d203c714 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination Pemetrexed elimination half-life is 3.5 hours in patients with normal renal function [creatinine clearance (CLcr) of 90 mL/min] with a total systemic clearance of 92 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9f34c00-1176-4f44-8cff-bae5bdc0c40f (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95633c32-89a8-4275-94e7-939c9f2e6135 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b185f459-5489-4e18-8521-1686b5d16f67 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495c6751-8d6f-4093-8108-9bed283fce03 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d8bcf03-e055-a274-7844-ae9a523e3c4c (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14974d4e-2f01-4e02-aea2-c28b3ca0781c (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ceacc3e-f555-489b-8b16-2baa58b2f5a5 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61588f3c-4c06-4c35-a000-201dd1019093 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:363665ca-db15-4123-84ac-0ae66b5f1363 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:737ead51-f73c-414f-b68f-d3affc27a225 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd0ada98-3237-4465-8ba2-3a12c33116fb (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a9b89d-7135-4e0c-b8e4-52580554769b (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe432994-e61b-4a87-8c98-cc20b847d0fe (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
Projected row 1187
- Medicine slug
- pemetrexed
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 32
- Source count
- 32
- Agreement rate
- 0.90625
- Recorded readings
16.1 liters
- Numeric value
- 16.1
- Unit
- L
- Source records
- 29
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 29 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f006b06-ab85-423d-ba0c-dfc3fc25844e (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfd19e67-54cb-c062-e053-2995a90a294a (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39219e4b-80a6-4d4f-96a3-1202e542d050 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0d000a3-b9d2-4fa9-9591-f7acb077481d (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fb3a2d5-b9ec-4044-abb9-3e0d848a448e (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64f4a9ed-26ff-4bc7-bef1-4faa98b35563 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cc1574b-3d2f-489b-9ad3-55695bb97200 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa8f1f52-3f05-4ae8-bfec-7f0a029e6825 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adc9ce4c-926a-4ee8-bd0d-d06fc89c17fc (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e087418-69ff-47fa-93c2-f28699309433 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae77f00f-d43b-4b75-afd5-a2a9cb7138da (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b660f68-b770-4e0a-b2f9-25e663deecc3 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ae68628-7ab0-4491-b3ae-6a8330b719c8 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5a860f3-37ec-429c-ae04-9c88d7c55c08 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ca1ce75-5284-4282-b76a-3700d203c714 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9f34c00-1176-4f44-8cff-bae5bdc0c40f (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95633c32-89a8-4275-94e7-939c9f2e6135 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b185f459-5489-4e18-8521-1686b5d16f67 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495c6751-8d6f-4093-8108-9bed283fce03 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d8bcf03-e055-a274-7844-ae9a523e3c4c (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14974d4e-2f01-4e02-aea2-c28b3ca0781c (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ceacc3e-f555-489b-8b16-2baa58b2f5a5 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61588f3c-4c06-4c35-a000-201dd1019093 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:363665ca-db15-4123-84ac-0ae66b5f1363 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:737ead51-f73c-414f-b68f-d3affc27a225 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd0ada98-3237-4465-8ba2-3a12c33116fb (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a9b89d-7135-4e0c-b8e4-52580554769b (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe432994-e61b-4a87-8c98-cc20b847d0fe (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters.
16.1 L
- Numeric value
- 16.1
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2308f4e8-21c8-49c1-a5b8-deb8610bac6a (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:caef07ce-066b-4c48-98dc-974b05ebbbe0 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed has a steady-state volume of distribution of 16.1 L.
16 L
- Numeric value
- 16
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3 (opens source in a new tab)
Pemetrexed label
Version not recorded · Effective date not recorded
Distribution Pemetrexed steady-state volume of distribution is 16 L.
Projected row 1188
- Medicine slug
- penciclovir
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
10 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72da67d0-1349-4408-be13-9935bd9c0179 (opens source in a new tab)
Penciclovir label
Version not recorded · Effective date not recorded
Penciclovir triphosphate has an intracellular half-life of 10 hours in HSV-1 and 20 hours in HSV-2 infected cells grown in culture.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d95b934-2ba6-41b9-928f-6d2ce12f93f5 (opens source in a new tab)
Penciclovir label
Version not recorded · Effective date not recorded
Penciclovir triphosphate has an intracellular half-life of 10 hours in HSV-1 and 20 hours in HSV-2 infected cells grown in culture.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61229829-55a0-4d6f-a423-4b48a2b4d8e5 (opens source in a new tab)
Penciclovir label
Version not recorded · Effective date not recorded
Penciclovir triphosphate has an intracellular half-life of 10 hours in HSV-1 and 20 hours in HSV-2 infected cells grown in culture.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9118bbe9-8231-40c8-b11a-6c4a5f41aa16 (opens source in a new tab)
Penciclovir label
Version not recorded · Effective date not recorded
Penciclovir triphosphate has an intracellular half-life of 10 hours in HSV-1 and 20 hours in HSV-2 infected cells grown in culture.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfbd90ed-4135-486a-807b-27c668154b2e (opens source in a new tab)
Penciclovir label
Version not recorded · Effective date not recorded
Penciclovir triphosphate has an intracellular half-life of 10 hours in HSV-1 and 20 hours in HSV-2 infected cells grown in culture.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9cb88c28-d9c9-45e3-b4fe-083327f122de (opens source in a new tab)
Penciclovir label
Version not recorded · Effective date not recorded
Penciclovir triphosphate has an intracellular half-life of 10 hours in HSV-1 and 20 hours in HSV-2 infected cells grown in culture.
Projected row 1189
- Medicine slug
- penicillamine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
1 to 3 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:064fb48d-aa34-4e52-9295-10f2ca4c77dc (opens source in a new tab)
Penicillamine label
Version not recorded · Effective date not recorded
The peak plasma concentration of penicillamine occurs 1 to 3 hours after ingestion; it is approximately 1 to 2 mg/L after an oral dose of 250 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:594d7a82-af1d-41c4-98ee-0ea6895fc237 (opens source in a new tab)
Penicillamine label
Version not recorded · Effective date not recorded
The peak plasma concentration of penicillamine occurs 1 to 3 hours after ingestion; it is approximately 1 to 2 mg/L after an oral dose of 250 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80e736d3-2017-4d68-94b4-38255c3c59c6 (opens source in a new tab)
Penicillamine label
Version not recorded · Effective date not recorded
The peak plasma concentration of penicillamine occurs 1 to 3 hours after ingestion; it is approximately 1 to 2 mg/L after an oral dose of 250 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c92335c6-f6fa-4768-9401-55c6b7f87699 (opens source in a new tab)
Penicillamine label
Version not recorded · Effective date not recorded
The peak plasma concentration of penicillamine occurs 1 to 3 hours after ingestion; it is approximately 1 to 2 mg/L after an oral dose of 250 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15d08594-83a9-cc7a-92ef-1bac0427e121 (opens source in a new tab)
Penicillamine label
Version not recorded · Effective date not recorded
The peak plasma concentration of penicillamine occurs 1 to 3 hours after ingestion; it is approximately 1 to 2 mg/L after an oral dose of 250 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddbd84a9-1c39-42e0-a271-138784e1dc58 (opens source in a new tab)
Penicillamine label
Version not recorded · Effective date not recorded
The peak plasma concentration of penicillamine occurs 1-3 hours after ingestion; it is approximately 1-2 mg/L after an oral dose of 250 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1320f46b-e243-4e93-b9c9-ad8eb7828de5 (opens source in a new tab)
Penicillamine label
Version not recorded · Effective date not recorded
The peak plasma concentration of penicillamine occurs 1 to 3 hours after ingestion; it is approximately 1 to 2 mg/L after an oral dose of 250 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f658b20a-269f-4e78-a79b-a56a5ed8dc1b (opens source in a new tab)
Penicillamine label
Version not recorded · Effective date not recorded
The peak plasma concentration of penicillamine occurs 1 to 3 hours after ingestion; it is approximately 1 to 2 mg/L after an oral dose of 250 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01e79d8f-8c74-4f48-b761-9f225fabf93d (opens source in a new tab)
Penicillamine label
Version not recorded · Effective date not recorded
The peak plasma concentration of penicillamine occurs 1-3 hours after ingestion; it is approximately 1-2 mg/L after an oral dose of 250 mg.
Projected row 1190
- Medicine slug
- pentamidine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
8 hour
- Numeric value
- 8
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc2b635e-4840-4dc3-a177-5484371680e8 (opens source in a new tab)
Pentamidine label
Version not recorded · Effective date not recorded
ngle two-hour intravenous infusion or after a single intramuscular injection to 12 patients with AIDS are presented in the following table: Mean ± SD Cmax ng/mL Clearance L/h Half-life hours Vdss L Concentration ng/mL 8 hour 24 hour 2 hour I.V. infusion 4 mg/kg (N=6) 612 ± 371 248 ± 91 6.4 ± 1.3 821 ± 535 19.3 ± 16.9 2.9 ± 1.4 I.M. 4 mg/kg (N=6) 209 ± 48 305 ± 81 9.4 ± 2.0 2724 ± 1066 22.9 ± 8.0 6
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb8e8155-5505-44d5-9dee-525e2e45b95d (opens source in a new tab)
Pentamidine label
Version not recorded · Effective date not recorded
gle two-hour intravenous infusion or after a single intramuscular injection to 12 patients with AIDS are presented in the following table: Mean ± SD C max ng/mL Clearance L/h Half-life hours Vdss L Concentration ng/mL 8 hour 24 hour 2 hour I.V. infusion 4 mg/kg (N=6) 612 ± 371 248 ± 91 6.4 ± 1.3 821 ± 535 19.3 ± 16.9 2.9 ± 1.4 I.M. 4 mg/kg (N=6) 209 ± 48 305 ± 81 9.4 ± 2.0 2724 ± 1066 22.9 ± 8.0 6
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d46aea4f-8f3f-4ce0-93d6-94e147f5a31a (opens source in a new tab)
Pentamidine label
Version not recorded · Effective date not recorded
gle two-hour intravenous infusion or after a single intramuscular injection to 12 patients with AIDS are presented in the following table: Mean ± SD C max ng/mL Clearance L/h Half-life hours Vdss L Concentration ng/mL 8 hour 24 hour 2 hour I.V. infusion 4 mg/kg (N=6) 612 ± 371 248 ± 91 6.4 ± 1.3 821 ± 535 19.3 ± 16.9 2.9 ± 1.4 I.M. 4 mg/kg (N=6) 209 ± 48 305 ± 81 9.4 ± 2.0 2724 ± 1066 22.9 ± 8.0 6
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:860c799c-5199-4f0c-b21b-9910273474d9 (opens source in a new tab)
Pentamidine label
Version not recorded · Effective date not recorded
gle two-hour intravenous infusion or after a single intramuscular injection to 12 patients with AIDS are presented in the following table: Mean ± SD C max ng/mL Clearance L/h Half-life hours Vdss L Concentration ng/mL 8 hour 24 hour 2 hour I.V. infusion 4 mg/kg (N=6) 612 ± 371 248 ± 91 6.4 ± 1.3 821 ± 535 19.3 ± 16.9 2.9 ± 1.4 I.M. 4 mg/kg (N=6) 209 ± 48 305 ± 81 9.4 ± 2.0 2724 ± 1066 22.9 ± 8.0 6
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c14fbf2-e21f-44b3-b35c-06919d40d7e0 (opens source in a new tab)
Pentamidine label
Version not recorded · Effective date not recorded
ngle two-hour intravenous infusion or after a single intramuscular injection to 12 patients with AIDS are presented in the following table: Mean ± SD Cmax ng/mL Clearance L/h Half-life hours Vdss L Concentration ng/mL 8 hour 24 hour 2 hour I.V. infusion 4 mg/kg (N=6) 612 ± 371 248 ± 91 6.4 ± 1.3 821 ± 535 19.3 ± 16.9 2.9 ± 1.4 I.M. 4 mg/kg (N=6) 209 ± 48 305 ± 81 9.4 ± 2.0 2724 ± 1066 22.9 ± 8.0 6
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1180Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.